申联生物：创新药UB-221注射液II期临床研究已完成全部受试者入组

Core Viewpoint - The company announced the completion of participant enrollment for the Phase II clinical trial of the innovative drug UB-221, indicating significant progress in its development [1] Group 1: Clinical Trial Progress - The company received a notification from its associate company, Shizhi Yuan, regarding the progress of the Phase II clinical trial for UB-221 [1] - A total of 145 participants have been enrolled in the clinical trial as of the date of the announcement [1] Group 2: Product and Commercial Rights - Shizhi Yuan holds all commercialization rights, including marketing authorization, research, production, and sales for UB-221 in mainland China [1] - UB-221 is a humanized monoclonal antibody developed as a subcutaneous injection, representing a next-generation product from the inventor of the anti-IgE treatment method, Dr. Zhang Ziwen [1] - The drug was originally developed by United Biomedical, Inc. (UBI), the company's second-largest shareholder [1]